Brought to you by 
GSK signs broad collaboration with Theravance
18 Oct 2022
Executive Summary
GlaxoSmithKline PLC and Theravance (developing drugs in several therapeutic areas), partners in the development of respiratory drugs since January 2003, have entered another agreement. Under terms of the new deal, which they are calling "Beyond Advair," GSK gets an exclusive worldwide development and marketing option to any of Theravance's current or future drug candidates through August 2007.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK signs broad collaboration with Theravance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice